Daily notebook from the J.P. Morgan Healthcare Conference: Gene therapy Vertex enters pricing negotiations on gene therapy, Sanofi sees opportunity
 

Pricing challenges, high taxes and the growing problem of drug shortages have led the pharmaceutical industry body Leem to come forward...
 

The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream

The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.

From a scientific perspective, the outlook for patient with rare disease has never been brighter. This year, 13 new cell or gene therapies could be approve...
 

Over the past month, the company has released positive clinical trial results and raised more cash, both of which will help on its way to combat melanoma.

US FDA commissioner tells J.P. Morgan conference that the agency, industry, and the entire healthcare system need to change ‘at the same time’... 

Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras.